Comparative Pharmacology
Head-to-head clinical analysis: ERYTHROMYCIN ESTOLATE versus PEDIAMYCIN 400.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYTHROMYCIN ESTOLATE versus PEDIAMYCIN 400.
ERYTHROMYCIN ESTOLATE vs PEDIAMYCIN 400
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin estolate is a macrolide antibiotic that reversibly binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation step. It may also exhibit immunomodulatory and anti-inflammatory effects.
Erythromycin binds to the 50S subunit of the bacterial ribosome and inhibits protein synthesis by blocking the translocation step.
250-500 mg orally every 6-12 hours
400 mg orally every 6 hours for 10 days.
None Documented
None Documented
Approximately 1.5-2 hours in normal adults; prolonged to 5-6 hours in end-stage renal disease.
1.5-2 hours; prolonged in renal impairment (up to 6 hours)
Primarily hepatic via biliary excretion into feces; approximately 2-5% excreted unchanged in urine. <5% renal elimination.
Renal (80-90% unchanged); biliary/fecal (minor, <5%)
Category A/B
Category C
Macrolide Antibiotic
Macrolide Antibiotic